| P/E (FY) | — | Sales (TTM) | $601,000 |
| Earnings (TTM) | -$18.6M | ROE | — |
| Net Margin | −3100.50% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −12.59% |
| Market Cap | $2.2M | Trading Days | 1992 |
| 52W High | 1.50 |
| 52W Low | 0.25 |
| % Off High | −44.83% |
| YTD | −23.37% | 1Y | −0.29% |
| 3Y | −98.60% | 5Y | −99.84% |
| Since incept. (ann.) | −63.23% |
| Ann. Volatility (1Y) | 270.34% | Ann. Volatility (3Y) | 211.84% |
| Sharpe (1Y) | 1.25 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −66.00% | Max Drawdown (3Y) | −99.45% |
| Beta (3Y, vs SPY) | 1.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OGEN | ORAGENICS INC | $2.2M | — |
| DCOY | Decoy Therapeutics Inc. | $2.1M | — |
| AZTR | Azitra, Inc. | $2.1M | — |
| BPTH | BIO-PATH HOLDINGS, INC. | $2.0M | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $1.9M | — |
| NXTS | Nexentis Technologies Inc. | $1.9M | — |
| GRI | GRI Bio, Inc. | $2.6M | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $1.7M | — |
| ACUT | Accustem Sciences Inc. | $3.1M | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $3.6M | — |
| ENSC | Ensysce Biosciences, Inc. | $3.7M |
| — |
| HEPA | Hepion Pharmaceuticals, Inc. | $1.3M | — |
